How to Regulate Drug Device Combination Product
What is a Drug-Device Combination Product?
A drug-device combination product is a therapeutic product that combines a drug, medical device, and sometimes a biologic into a single integrated product, co-packaged product, or cross-labeled system. Regulatory authorities such as the FDA, European Medicines Agency (EMA), and other global agencies determine the applicable regulatory pathway based on the product’s Primary Mode of Action (PMOA), intended use, and associated risks.
Talk to our experts
Key Takeaways
✔ Drug-device combination products are regulated differently across countries.
✔ Determining the Primary Mode of Action (PMOA) is the first and most critical regulatory step.
✔ Regulatory requirements may involve both medicinal product and medical device legislation.
✔ Manufacturers must prepare comprehensive technical documentation, risk management files, and quality management system documentation.
✔ Early regulatory planning reduces approval timelines, development costs, and compliance risks.
Introduction
The healthcare industry is rapidly adopting drug-device combination products that improve treatment effectiveness, simplify administration, and enhance patient outcomes. Products such as prefilled syringes, insulin pens, drug-eluting stents, and transdermal patches combine the therapeutic benefits of a drug with the functionality of a medical device.
However, these products face complex regulatory requirements because they often fall under both drug and medical device regulations. Manufacturers must determine the Primary Mode of Action (PMOA), select the appropriate regulatory pathway, prepare integrated technical documentation, and comply with region-specific quality and regulatory standards.
This guide explains how drug-device combination products are regulated across major global markets and provides practical insights to help manufacturers achieve compliance and accelerate successful market entry.
What is a Drug-Device Combination Product?
A drug-device combination product combines a medicinal product and a medical device into a single therapeutic solution. Some combination products may also include a biologic component. These products are designed to improve treatment outcomes by integrating drug therapy with device functionality.
Common types include:
- Single-entity combination products
- Co-packaged combination products
- Cross-labeled combination products
- Drug-biologic-device combination products
Regulatory authorities classify these products based on their intended use, design, risk profile, and Primary Mode of Action (PMOA), which determines the applicable regulatory pathway.
Because combination products involve both pharmaceutical and medical device requirements, manufacturers should incorporate regulatory planning early in product development to ensure compliance and accelerate market access.
Early regulatory strategy is often the difference between an efficient approval process and costly redevelopment. Determining the correct classification and regulatory pathway before design verification can significantly reduce submission delays, additional testing, and post-development modifications.
Quick Facts
Aspect | Summary |
Product Type | Drug + Device (± Biologic) |
Main Regulatory Decision | Primary Mode of Action (PMOA) |
Major Markets | FDA, EU MDR, MHRA, SFDA, CDSCO |
Key Standards | ISO 13485, ISO 14971 |
Documentation | Technical Documentation + Risk Management + Clinical Evidence |
Commercial Goal | Safe and compliant global market access |
Planning to Develop a Drug-Device Combination Product?
Whether you’re developing a novel combination product, expanding into new markets, or preparing for regulatory submissions, a well-defined regulatory strategy can significantly reduce approval timelines and compliance risks. Operon Strategist supports manufacturers with regulatory planning, technical documentation, quality management systems, CE Marking, and global market access for drug-device combination products
Schedule a Compliance Consultation
Accelerate Market Access with End-to-End Regulatory Guidance
Types of Drug-Device Combination Products
Drug-device combination products are classified based on how the drug, device, and biologic components are integrated and marketed. The four main categories are:
Single-Entity Combination Products
These products physically combine the drug and device into a single unit designed to function together.
Examples:
- Prefilled syringes
- Insulin pens
- Drug-eluting stents
- Metered-dose inhalers
- Auto-injectors
Manufacturers must demonstrate the safety, performance, and effectiveness of both the drug and device as an integrated product.
Co-Packaged Combination Products
These consist of separate drug and device components packaged together for use as a single therapeutic system.
Examples:
- Surgical kits with drugs and devices
- Procedure packs
- Dialysis kits with medicinal products
- Convenience kits
Although physically separate, regulators evaluate them as one combined product.
Cross-Labeled Combination Products
These involve separately marketed drugs and devices that are intended to be used together through labeling or instructions for use.
Examples:
- Drug infusion systems
- Software-controlled injector systems
- External drug delivery devices
Regulatory authorities assess the combined safety and performance of both components.
Drug-Biologic-Device Combination Products
These advanced therapies integrate a drug, biologic, and medical device into a single treatment solution.
Examples:
- Vaccine delivery systems
- Cell therapy delivery devices
- Gene therapy administration platforms
- Combination immunotherapy systems
Due to their complexity, these products often require review by multiple regulatory authorities or specialized review divisions.
Quick Comparison
Combination Product Type | Description | Common Examples |
Single-Entity | Drug and device physically integrated | Insulin pen, prefilled syringe |
Co-Packaged | Separate products packaged together | Surgical kits, convenience kits |
Cross-Labeled | Components marketed separately but intended for combined use | Infusion systems |
Drug-Biologic-Device | Drug, biologic, and device integrated | Vaccine delivery systems |
Common Examples of Drug-Device Combination Products
Many patients use drug-device combination products every day without realizing that these products are regulated under specialized regulatory pathways.
Some of the most widely recognized examples include:
Drug Delivery Devices
- Prefilled syringes
- Auto-injectors
- Pen injectors
- Wearable injectors
- Infusion pumps
Cardiovascular Products
- Drug-eluting stents
- Drug-coated balloons
- Implantable infusion systems
Respiratory Products
- Dry powder inhalers
- Metered-dose inhalers
- Nebulizer systems supplied with medicinal products
Diabetes Management
- Insulin pens
- Smart insulin delivery devices
- Continuous insulin infusion systems
Transdermal Drug Delivery
- Nicotine patches
- Hormone replacement patches
- Pain management patches
- Fentanyl delivery systems
Ophthalmic Products
- Drug-eluting ocular implants
- Intravitreal injection systems
Oncology
- Targeted chemotherapy delivery devices
- Implantable drug reservoirs
Vaccine Delivery
- Needle-free injectors
- Safety syringes
- Advanced biologic delivery systems
The future of healthcare is increasingly focused on integrated therapies rather than standalone drugs or devices. Manufacturers developing next-generation products should consider regulatory requirements alongside product design from the earliest concept stage, as changes made later in development can significantly increase costs and delay commercialization.
Why Regulatory Classification Matters
One of the most common reasons for regulatory delays is incorrect product classification.
Many manufacturers assume that adding a medical device to a medicinal product—or vice versa—automatically determines the applicable regulatory pathway. In reality, regulatory authorities assess the product based on multiple factors, including:
- Intended purpose
- Mechanism of action
- Design characteristics
- Therapeutic claims
- Risk profile
- How the product is supplied to users
An incorrect regulatory strategy can lead to:
- Additional testing requirements
- Requests for supplementary documentation
- Extended review timelines
- Increased development costs
- Delayed market entry
- Reclassification during regulatory review
Early regulatory planning helps manufacturers identify the appropriate pathway before significant investments are made in product development.
How Are Drug-Device Combination Products Regulated?
Unlike standalone pharmaceuticals or medical devices, drug-device combination products are regulated using a risk-based approach that considers the product as an integrated therapeutic solution. The applicable regulatory pathway depends on how the drug and device components work together to achieve the intended medical purpose.
While regulatory frameworks differ across regions, most authorities evaluate the following factors:
- Intended use and therapeutic claims
- Product composition
- Mechanism of action
- Level of integration between the drug and device
- Risk profile
- Manufacturing process
- Clinical evidence
- Primary Mode of Action (PMOA)
Among these, Primary Mode of Action (PMOA) is the most important because it determines which regulatory framework will primarily govern the product.
What Is the Primary Mode of Action (PMOA)?
The Primary Mode of Action (PMOA) is the principal therapeutic action responsible for achieving the product’s intended medical purpose.
Simply put, regulators ask:
Which component contributes the greatest therapeutic effect—the drug, the medical device, or the biologic?
The answer determines which regulatory pathway applies.
For example:
Product | Primary Therapeutic Effect | Likely PMOA |
Drug-eluting stent | Mechanical opening of the artery | Device |
Prefilled syringe | Drug treats the disease; syringe delivers it | Drug |
Insulin pen | Insulin controls blood glucose | Drug |
Drug-coated balloon | Mechanical dilation with drug support | Device (case-specific) |
Transdermal patch | Drug absorbed through the skin | Drug |
Although many combination products contain sophisticated delivery devices, the device does not automatically become the primary regulated component. Regulators assess the overall therapeutic purpose rather than simply counting the number of components.
Why PMOA Is Critical
Determining PMOA influences almost every aspect of the regulatory strategy, including:
- Applicable legislation
- Lead regulatory authority
- Documentation requirements
- Clinical evidence expectations
- Quality management requirements
- Conformity assessment pathway
- Regulatory review timelines
- Post-market obligations
Selecting the wrong PMOA can result in regulatory questions, additional testing, delayed approvals, or even reclassification during the review process.
PMOA should be evaluated during the concept and feasibility stage—not after product development is complete. Early classification supports better design decisions, regulatory planning, and market entry strategies.
Global Regulatory Framework for Drug-Device Combination Products
Although regulatory authorities share common principles, each jurisdiction has its own legislation, review process, and documentation requirements.
Manufacturers planning international commercialization should develop a regulatory strategy that accommodates regional differences while maintaining consistent product quality, safety, and performance.
The following overview summarizes how major markets regulate drug-device combination products.
Global Regulatory Comparison
Region | Primary Regulatory Authority | Main Framework |
United States | FDA | Combination Product Regulations |
European Union | European Commission, EMA & Notified Bodies | EU MDR 2017/745 and pharmaceutical legislation |
United Kingdom | MHRA | UK MDR and medicines legislation |
Saudi Arabia | SFDA | Medical Device Interim Regulation and related guidance |
India | CDSCO | Medical Device Rules and Drugs & Cosmetics framework |
Drug-Device Combination Products Under FDA Regulations
In the United States, the Food and Drug Administration (FDA) regulates combination products through the Office of Combination Products (OCP).
The FDA determines:
- Product classification
- Primary Mode of Action
- Lead review center
- Applicable regulatory requirements
Depending on the PMOA, the product may be assigned to:
- Center for Drug Evaluation and Research (CDER)
- Center for Devices and Radiological Health (CDRH)
- Center for Biologics Evaluation and Research (CBER)
The assigned center coordinates the review while collaborating with other FDA centers when additional expertise is required.
Manufacturers are encouraged to engage with the FDA early, particularly for novel products or technologies where classification may not be straightforward.
Drug-Device Combination Products Under EU Regulations
Within the European Union, drug-device combination products are regulated under a combination of:
- EU Medical Device Regulation (EU MDR 2017/745)
- Medicinal product legislation
- EMA guidance
- Article 117 requirements, where applicable
Unlike the FDA’s centralized Office of Combination Products, the European regulatory system involves collaboration between:
- Competent Authorities
- European Medicines Agency (EMA)
- Notified Bodies
- Marketing Authorization Holders
The regulatory pathway depends on several factors, including:
- Product design
- Degree of integration
- PMOA
- Whether the device component requires a Notified Body Opinion
- Applicable conformity assessment procedures
Manufacturers must ensure that the device component complies with relevant EU MDR requirements while supporting the medicinal product authorization where required.
Regulatory Considerations in Other Global Markets
Many regulatory authorities align portions of their requirements with internationally recognized principles while maintaining country-specific submission procedures.
For example:
United Kingdom (MHRA)
The MHRA evaluates combination products under UK medical device and medicines legislation, with requirements influenced by product classification and intended purpose.
Saudi Arabia (SFDA)
The Saudi Food and Drug Authority (SFDA) requires manufacturers to demonstrate compliance with applicable regulatory requirements before market authorization. Products may require technical documentation, quality management evidence, and supporting conformity assessment records depending on classification.
India (CDSCO)
India regulates medical devices under the Medical Device Rules, while medicinal products are governed under the Drugs and Cosmetics framework. Combination products require careful regulatory assessment to determine the applicable pathway and documentation requirements.
Why a Regulatory Strategy Matters
Developing a regulatory strategy at the beginning of product development helps manufacturers:
- Select the appropriate regulatory pathway
- Identify documentation requirements
- Reduce approval timelines
- Minimize compliance risks
- Avoid costly design changes
- Accelerate global market access
Engaging regulatory experts early enables manufacturers to make informed decisions throughout the product lifecycle, from concept and design to commercialization and post-market compliance.
Why a Regulatory Strategy Matters
Developing a regulatory strategy at the beginning of product development helps manufacturers:
- Select the appropriate regulatory pathway
- Identify documentation requirements
- Reduce approval timelines
- Minimize compliance risks
- Avoid costly design changes
- Accelerate global market access
Engaging regulatory experts early enables manufacturers to make informed decisions throughout the product lifecycle, from concept and design to commercialization and post-market compliance.
How Operon Strategist Supports Drug-Device Combination Product Compliance
Successfully bringing a drug-device combination product to market requires more than meeting regulatory requirements. It demands a well-planned strategy that integrates product development, quality management, technical documentation, risk management, and global regulatory compliance from the earliest stages.
Our expertise includes:
- Drug-device combination product regulatory strategy
- Product classification and Primary Mode of Action (PMOA) assessment
- Technical documentation preparation and review
- EU MDR and Article 117 compliance support
- CE Marking strategy for combination products
- Quality Management System (ISO 13485) implementation
- Risk management documentation aligned with ISO 14971
- Design History File (DHF) and design documentation
- Global regulatory submissions, including FDA, EU, UK, SFDA, and CDSCO pathways
- Regulatory due diligence for product development and commercialization
Need expert support for your drug-device combination product? Contact Operon Strategist to develop a tailored regulatory strategy, prepare compliant technical documentation, and confidently navigate global regulatory requirements.
Ensure Seamless Regulatory Compliance for Your Device
Get Your Medical Device Market-Ready with Expert Regulatory Support
FAQ's
What is a drug-device combination product?
It’s a therapeutic product that brings together a drug, a medical device, and sometimes a biologic into one integrated solution — think prefilled syringes, insulin pens, or drug-eluting stents. Regulators decide how to classify and review it based on intended use, risk, and how the components work together.
What are the main types of combination products?
Four categories: single-entity (drug and device physically combined, like an auto-injector), co-packaged (separate components sold together, like a surgical kit), cross-labeled (separately marketed products meant to be used together, like an infusion system), and drug-biologic-device products (like vaccine or gene therapy delivery systems).
What is Primary Mode of Action (PMOA), and why does it matter so much?
PMOA is the main therapeutic action responsible for the product’s intended effect — is it the drug, the device, or a biologic doing the heavy lifting? It determines which regulatory framework and lead authority govern the product, so getting it right early avoids reclassification, extra testing, and delays later.
Who regulates combination products in the U.S.?
The FDA’s Office of Combination Products decides classification and PMOA, then assigns the review to CDER, CDRH, or CBER depending on which component drives the therapeutic effect.
How does the EU regulate these products?
Through a mix of EU MDR 2017/745, medicinal product legislation, EMA guidance, and Article 117 requirements where relevant. Unlike the FDA’s centralized office, EU review involves coordination between Competent Authorities, the EMA, and Notified Bodies.